Venlafaxine poisoning-induced severe hypoglycemia in a non-diabetic patient: a case report

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 167

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_PJMT-9-3_006

تاریخ نمایه سازی: 19 بهمن 1399

Abstract:

Abstract Introduction: Venlafaxine is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive episodes and anxiety. The risk of hypoglycemia is mentioned in the Summary of Product Characteristics (SmPC) of venlafaxine in the “warnings and precautions” section in diabetic patients. This effect appears neither in the “adverse reactions” nor in the “overdose” section. We herein report a case of severe hypoglycemia with coma in relation to venlafaxine poisoning.  Case Report: A 35-year-old non-diabetic obese woman (BMI, 29 kg/m2) was found unconscious a few hours after ingesting venlafaxine and bromazepam in a suicide attempt. Vital signs on day 1 were as follows: Glasgow Coma score of 7, blood pressure of 99/66 mmHg and heart rate of 100/min. Electrocardiogram showed no abnormality. She was admitted to the intensive care unit. Due to sustained hypoglycemia [0.5 g/L (day1); 0.41 g/L (day2); 0.8 to 1.20 (day3)], she received continuous intravenous 10% glucose infusion for 3 days to normalize blood glucose. Plasma venlafaxine concentration was 11.7 times the upper the limit of therapeutic dose range (UTDR) on day 2 and reached the therapeutic dose range (TDR) on day 6. Plasma bromazepam concentration was 6.7 times UTDR on day 3 and reached TDR on day 8. Alternative etiologies of hypoglycemia were excluded, i.e. hypoglycemic sulfonamide, insulin poisoning, insulinoma, and disease of the adrenal gland, liver and thyroid. She was transferred to a psychiatric unit after one week. Discussion: Impairment of blood glucose homeostasis is rarely described with venlafaxine. In our patient, hypoglycemia appeared to be correlated with plasma venlafaxine concentrations and may be explained by increased insulin sensitivity, considering her obesity. Conclusion: Healthcare professionals should be aware of hypoglycemia induced by venlafaxine or other SNRIs in non-diabetic patients.

Authors

- -

Regional Pharmacovigilance Center, Fernand-Widal Hospital, APHP, ۲۰۰ rue du Faubourg Saint-Denis, ۷۵۴۷۵ Cedex ۱۰, Paris, France

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1.Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of ...
  • 2. Gomez R, Huber J, Tombini G, Barros HMT. Acute ...
  • 3. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant ...
  • 5. Deeg MA, Lipkin EW. Hypoglycemia associated with the use ...
  • 6. Fernández Lópeza MI, Sánchez Esteban J, Jímenez Belló J, ...
  • 7. Sawka AM, Burgart V, Zimmerman D. Loss of hypoglycemia ...
  • 8. Zuccoli ML, Milano G, Leone S, Fucile C, Brasesco ...
  • 10. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The ...
  • 11. Brvar M, Koželj G, Mašič LP. Hypoglycemia in venlafaxine ...
  • 12. Francino MC, Bretaudeau Deguigne M, Badin J, Turcant A, ...
  • 13. Meertens JH, Monteban-Kooistra WE, Ligtenberg JJ, Tulleken JE, Zijlstra ...
  • 15. Stapel B, Gorinski N, Gmahl N, Rhein M, Preuss ...
  • 16. Odonkor CA, Chhatre A. What's Tramadol Got to Do ...
  • 17. Senthilkumaran S, Ananth C, Menezes RG, Thirumalaikolundusubramanian P. Tramadol-induced ...
  • 20. Olguner EkerÖ, Özsoy S, Eker B, Doğan H. Metabolic ...
  • 21. Schiemsky T, Vundelinckx G, Croes K, Penders J, Desmet ...
  • 22. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: ...
  • 23. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Drug ...
  • 24. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics ...
  • نمایش کامل مراجع